Search hospitals > Iowa > Davenport
Genesis Cancer Care Institute
Claim this profileDavenport, Iowa 52804
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Colorectal Cancer
42 reported clinical trials
1 medical researcher
Summary
Genesis Cancer Care Institute is a medical facility located in Davenport, Iowa. This center is recognized for care of Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Colorectal Cancer and other specialties. Genesis Cancer Care Institute is involved with conducting 42 clinical trials across 59 conditions. There are 1 research doctors associated with this hospital, such as David M. Spector.Area of expertise
1Cancer
Global LeaderStage III
Stage IV
Stage II
2Breast Cancer
Global LeaderHER2 positive
ER positive
ER negative
Top PIs
Clinical Trials running at Genesis Cancer Care Institute
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
ALK Gene Rearrangement
Squamous Cell Carcinoma
Lung Adenocarcinoma
Lung Carcinoma
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Genesis Cancer Care Institute?
Genesis Cancer Care Institute is a medical facility located in Davenport, Iowa. This center is recognized for care of Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Colorectal Cancer and other specialties. Genesis Cancer Care Institute is involved with conducting 42 clinical trials across 59 conditions. There are 1 research doctors associated with this hospital, such as David M. Spector.